Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP2015 versus Enbrel in moderate to severe chronic plaque psoriasis
2012-002011-26Phase 3Completed
- Sponsor
- Hexal AG
- Start
- Mar 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of etanercept, omalizumab biosimilar SYN008 in psoriasis, sponsored by Hexal AG. Started Mar 2013; status: completed.
02
Drugs
etanerceptomalizumab biosimilar SYN008
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2012-002011-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002011-26.